LpxH Targeting Compounds for Resistant Gram-Negative Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial agents are inadequate for effectively treating multi- and pan-drug resistant Gram-negative bacterial infections due to their limited efficacy and toxicity profile, necessitating the development of new therapeutic approaches that target specific enzymes in lipid A biosynthesis.
Innovation Solution
Development of LpxH targeting compounds that inhibit downstream lipid A enzymes, disrupting the essential pathway of lipid A biosynthesis and leading to the accumulation of toxic lipid A intermediates, thereby providing an independent mechanism of bacterial killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antimicrobial agents are used to treat Gram-negative bacterial infections, then treatment is provided for susceptible bacteria, but efficacy is limited against multi- and pan-drug resistant strains
Solution Approach 1:
The patent extracts and targets a specific enzyme (LpxH) in the lipid A biosynthesis pathway that is essential for Gram-negative bacteria but absent in human cells. By focusing on this specific bacterial enzyme rather than broad-spectrum mechanisms, the compounds achieve selective efficacy against multi-drug resistant strains while avoiding resistance development through alternative pathways
Solution Approach 2:
The patent employs compounds with specific molecular parameters and structural features designed to optimally inhibit LpxH enzyme activity. The compounds contain specific functional groups and stereochemical configurations that match the LpxH active site, enabling potent inhibition with nanomolar IC50 values against resistant bacterial strains
2Reliability
If antibiotics targeting LpxC are used to disrupt lipid A biosynthesis, then antimicrobial activity is improved, but toxicity profile becomes a concern
Solution Approach 1:
The patent segments the lipid A biosynthesis pathway and targets a downstream enzyme (LpxH) rather than the upstream LpxC enzyme. This segmentation allows disruption of essential lipid A production while avoiding the toxic side effects associated with LpxC inhibition, as LpxH inhibition produces a different pattern of intermediate accumulation that is less harmful to host cells
Solution Approach 2:
The patent converts the potential harm of lipid A intermediate accumulation into a beneficial killing mechanism. By inhibiting LpxH, toxic lipid A intermediates accumulate in the bacterial inner membrane, creating membrane disruption and cell death. This controlled accumulation serves as the therapeutic mechanism rather than a harmful side effect
3Reliability
If LpxH targeting compounds are developed to disrupt lipid A biosynthesis, then independent mechanism of bacterial killing is achieved, but complexity of compound structure increases
Solution Approach 1:
The patent uses the LpxH enzyme as an intermediary target between the administered compound and the ultimate effect on bacterial cell death. The compounds do not directly kill bacteria but instead mediate their effect through specific binding to and inhibition of LpxH, which then triggers downstream events including toxic intermediate accumulation and membrane disruption
Solution Approach 2:
Instead of designing compounds that directly disrupt bacterial membranes or inhibit protein synthesis, the patent inverts the approach by designing compounds that inhibit an enzyme (LpxH) which then indirectly causes bacterial death through metabolic disruption and toxic intermediate accumulation. This indirect mechanism simplifies compound design while achieving reliable killing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LpxH targeting compounds demonstrate significant antimicrobial activity against a wide range of Gram-negative bacteria, including multi- and pan-drug resistant strains, offering a promising solution to the growing public health threat of Gram-negative bacterial infections.
Implementation Method 1
LpxH is a member of the calcineurin-like phosphatases (CLPs), which catalyzes the hydrolysis of UDP-2,3-diacyl-glucosamine (UDP-DAGn) to yield lipid X and UMP
Data Source
AI summary
LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selected from a single bond, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, and C1 to C10 substituted alkyl; Rc comprises hydrogen, halogen, —OH, —CO2CH3, —COOH, —CN2CF3, —CF3, —C2OH, —CONHOH, —CCOH, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, or C1 to C10 substituted alkyl; and Rd and Re are independently hydrogen, —OH, —COH, —COH, —COC, —COOH, Rf, or are taken together as an unsubstituted or substituted four to eight member nitrogen containing heterocycle ring.